Keywords: Astellas, Medivation, Enzalutamide, Prostate cancer, Ph III

Phase III study shows enzalutamide offers significant benefit in prostate cancer

Article | 17 August 2012

Print This

USA-based Medivation (Nasdaq: MDVN) and Japanese drug major Astellas (TSE: 4503) has announced the publication in the New England Journal of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in